Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Ventyx Biosciences Inc (VTYX)

Ventyx Biosciences Inc (VTYX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 148,015
  • Shares Outstanding, K 71,161
  • Annual Sales, $ 0 K
  • Annual Income, $ -135,120 K
  • EBIT $ -137 M
  • EBITDA $ -135 M
  • 60-Month Beta 0.93
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.64

Options Overview Details

View History
  • Implied Volatility 121.03% ( -33.10%)
  • Historical Volatility 113.04%
  • IV Percentile 57%
  • IV Rank 12.17%
  • IV High 796.79% on 04/07/25
  • IV Low 27.41% on 08/08/24
  • Put/Call Vol Ratio 0.18
  • Today's Volume 100
  • Volume Avg (30-Day) 1,698
  • Put/Call OI Ratio 0.04
  • Today's Open Interest 21,112
  • Open Int (30-Day) 20,592

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/25
See More
  • Average Estimate -0.43
  • Number of Estimates 6
  • High Estimate -0.36
  • Low Estimate -0.53
  • Prior Year -0.45
  • Growth Rate Est. (year over year) +4.44%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.95 +4.62%
on 07/02/25
2.75 -25.82%
on 06/10/25
-0.42 (-17.07%)
since 06/06/25
3-Month
0.83 +145.78%
on 04/08/25
2.75 -25.82%
on 06/10/25
+1.20 (+143.99%)
since 04/07/25
52-Week
0.78 +160.54%
on 04/07/25
3.39 -39.82%
on 12/06/24
-0.14 (-6.42%)
since 07/05/24

Most Recent Stories

More News
Ventyx Biosciences Announces Positive Top-Line Data from its Phase 2a Safety and Biomarker Trial Evaluating VTX3232 in Patients with Early-Stage Parkinson’s Disease

VTYX : 2.04 (-1.92%)
Ventyx Biosciences to Participate in the Jefferies Global Healthcare Conference

VTYX : 2.04 (-1.92%)
Ventyx Biosciences Reports First Quarter 2025 Financial Results and Highlights Recent Corporate Progress

VTYX : 2.04 (-1.92%)
Ventyx Biosciences Expands SAB with Renowned NLRP3 Experts and Prominent Neurodegenerative and Cardiometabolic Disease Specialists

VTYX : 2.04 (-1.92%)
Ventyx Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Corporate Progress

VTYX : 2.04 (-1.92%)
Ventyx Biosciences Announces Presentation of Data from the Phase 2 Trial of Allosteric TYK2 Inhibitor VTX958 in Crohn’s Disease at ECCO 2025

VTYX : 2.04 (-1.92%)
Ventyx Biosciences to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

VTYX : 2.04 (-1.92%)
Ventyx Biosciences Highlights 2025 Pipeline Strategy and Provides Clinical Updates on its NLRP3 Inhibitor Portfolio

VTYX : 2.04 (-1.92%)
Insider Purchase: CEO AND PRESIDENT of $VTYX (VTYX) Buys 238,248 Shares

Raju Mohan, the CEO AND PRESIDENT of $VTYX ($VTYX), bought 238,248 shares of the company on 11-22-2024. This trade was reported by Quiver Quantitative using data from a recent SEC filing. This increased...

VTYX : 2.04 (-1.92%)
Ventyx Biosciences to Participate in Three Upcoming Investor Conferences

VTYX : 2.04 (-1.92%)

Business Summary

Ventyx Biosciences Inc. is a clinical-stage biopharmaceutical company. It focused on advancing new therapies for patients living with inflammatory diseases and autoimmune disorders. The company's clinical stage pipeline includes VTX958, VTX002 and VTX2735. Ventyx Biosciences Inc. is headquartered in...

See More

Key Turning Points

3rd Resistance Point 2.21
2nd Resistance Point 2.16
1st Resistance Point 2.10
Last Price 2.04
1st Support Level 1.99
2nd Support Level 1.94
3rd Support Level 1.88

See More

52-Week High 3.39
Fibonacci 61.8% 2.39
Fibonacci 50% 2.09
Last Price 2.04
Fibonacci 38.2% 1.78
52-Week Low 0.78

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar